Nutriband Inc. (NTRB) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended July 31, 2025. Nutriband Inc. is a Nevada corporation focused on developing transdermal pharmaceutical products using its proprietary AVERSA abuse-deterrent technology. The company operates through two primary segments: Pocono Pharmaceuticals (contract manufacturing and sales of goods) and 4P Therapeutics (research and development). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended July 31, 2025 | Six Months Ended July 31, 2025 |
|---|---|---|
| Revenue | $622,452 | $1,289,884 |
| Gross Profit | $156,881 | $408,862 |
| Gross Margin | 25.2% | 31.7% |
| Net Loss | $(2,000,337) | $(3,389,206) |
| Net Loss Available to Common Stockholders | $(23,814,503) | $(25,203,372) |
| Diluted EPS (Common) | $(2.12) | $(2.26) |
| Cash and Cash Equivalents | $6,995,101 (as of July 31, 2025) | - |
| Working Capital | $5,948,628 | - |
| Total Debt (Current + Long-Term) | $175,659 | - |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 40.6% year-over-year for the three months ended July 31, 2025 ($622k vs. $443k), driven by higher demand in the Pocono Pharmaceuticals segment. The 4P Therapeutics segment generated no revenue in the current period.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses surged to $1.60M for the quarter (up from $737k in Q2 2024), primarily due to increased compensation-based expenses. Research and Development (R&D) expenses decreased to $563k (from $774k) due to reduced labor costs.
- Preferred Stock Dividend: A significant non-cash event occurred with the issuance of a preferred stock dividend valued at $21,814,166. This resulted in a massive increase in the net loss available to common stockholders, though it did not impact cash flow.
- Liquidity Improvement: Cash and cash equivalents increased from $4.31M (Jan 31, 2025) to $6.99M (July 31, 2025), bolstered by $5.3M in proceeds from warrant exercises.
Guidance, Outlook, and Risks
- Product Development: The company is advancing its lead product, AVERSA Fentanyl, in partnership with Kindeva Drug Delivery. An amended agreement reduced the remaining budget for NDA submission to $3.6M and added a $3.0M milestone payment upon FDA approval.
- Going Concern: Management believes substantial doubt about the company's ability to continue as a going concern is alleviated by current cash levels ($6.99M) and the ability to raise additional capital.
- Internal Controls: The company disclosed that its disclosure controls and procedures are not effective due to material weaknesses, including a lack of segregation of duties and reliance on third-party consultants. Remediation efforts are underway.
- Legal Proceedings: The company is a defendant in a lawsuit by Joseph Gunnar, LLC and Lucosky Brookman LLP seeking over $500,000 in damages. The company has filed counterclaims seeking $2M. The case is in the discovery stage.
- Management Change: CEO Gareth Sheridan stepped aside temporarily in August 2025 to campaign for the Irish Presidency. Co-founder and Chairman Serguei Melnik assumed CEO responsibilities.
Investor Verification Checklist
- Verify the valuation methodology used for the $21.8M preferred stock dividend and its impact on future dilution.
- Confirm the timeline and budget status for the AVERSA Fentanyl NDA submission with Kindeva.
- Review the status of the internal control remediation plan to address material weaknesses.
- Monitor the outcome of the pending litigation with Joseph Gunnar, LLC.
- Assess the sustainability of SG&A expense levels relative to current revenue growth.